The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
Helei Hou,* Dantong Sun,* Kewei Liu, Man Jiang, Dong Liu, Jingjuan Zhu, Na Zhou, Jing Cong, Xiaochun ZhangDepartment of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, People’s Republic of China*These authors contributed equally to this workBac...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-05-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/the-safety-and-serious-adverse-events-of-approved-alk-inhibitors-in-ma-peer-reviewed-article-CMAR |
id |
doaj-c0c941c587ca48fa840bfb4f20bb1037 |
---|---|
record_format |
Article |
spelling |
doaj-c0c941c587ca48fa840bfb4f20bb10372020-11-25T00:29:53ZengDove Medical PressCancer Management and Research1179-13222019-05-01Volume 114109411845647The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysisHou HSun DLiu KJiang MLiu DZhu JZhou NCong JZhang XHelei Hou,* Dantong Sun,* Kewei Liu, Man Jiang, Dong Liu, Jingjuan Zhu, Na Zhou, Jing Cong, Xiaochun ZhangDepartment of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, People’s Republic of China*These authors contributed equally to this workBackground: A total of 2%–7% of non-small cell lung cancer (NSCLC) patients have anaplastic lymphoma kinase (ALK) mutations. At present, three or more generations of ALK inhibitors have been used for ALK-positive NSCLC treatment, including crizotinib, alectinib, ceritinib, and brigatinib. Although most adverse events (AEs) of ALK inhibitors are grades 1 to 2 and generally can be well tolerated, serious adverse events (SAEs) of ALK inhibitors lack data analysis, and the lung toxicity of ALK inhibitors needs attention. Thus, we performed this meta-analysis to evaluate the safety of ALK inhibitors, especially in terms of drug-related SAEs.Methods: A total of 19 studies from 4 databases (PubMed, Science Direct, ClinicalTrials.gov and Cochrane Library) were included in this meta-analysis. All statistical analyses in this meta-analysis were performed with the STATA 14.0 software. We analyzed the incidences of total AEs, total SAEs and SAEs for different ALK inhibitors.Results: AEs of the ALK inhibitors occurred in almost all participants, and SAEs occurred in more than 20% of the participants. For ceritinib and brigatinib, SAEs occurred in more than 40% of the participants. Alectinib is most likely the safest of the two generations of ALK inhibitors. Generally, the ALK inhibitors showed significant lung toxicity.Conclusion: In conclusion, attention should be focused on ALK inhibitor-related SAEs, especially lung toxicity. According to this meta-analysis, alxectinib seems to be the safest ALK inhibitor. Physicians should focus on the related SAEs when prescribing ALK inhibitors.Keywords: ALK inhibitors, safety, serious adverse events, lung toxicityhttps://www.dovepress.com/the-safety-and-serious-adverse-events-of-approved-alk-inhibitors-in-ma-peer-reviewed-article-CMARALK inhibitorsadverse eventsserious adverse eventslung toxicity |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hou H Sun D Liu K Jiang M Liu D Zhu J Zhou N Cong J Zhang X |
spellingShingle |
Hou H Sun D Liu K Jiang M Liu D Zhu J Zhou N Cong J Zhang X The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis Cancer Management and Research ALK inhibitors adverse events serious adverse events lung toxicity |
author_facet |
Hou H Sun D Liu K Jiang M Liu D Zhu J Zhou N Cong J Zhang X |
author_sort |
Hou H |
title |
The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis |
title_short |
The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis |
title_full |
The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis |
title_fullStr |
The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis |
title_full_unstemmed |
The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis |
title_sort |
safety and serious adverse events of approved alk inhibitors in malignancies: a meta-analysis |
publisher |
Dove Medical Press |
series |
Cancer Management and Research |
issn |
1179-1322 |
publishDate |
2019-05-01 |
description |
Helei Hou,* Dantong Sun,* Kewei Liu, Man Jiang, Dong Liu, Jingjuan Zhu, Na Zhou, Jing Cong, Xiaochun ZhangDepartment of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, People’s Republic of China*These authors contributed equally to this workBackground: A total of 2%–7% of non-small cell lung cancer (NSCLC) patients have anaplastic lymphoma kinase (ALK) mutations. At present, three or more generations of ALK inhibitors have been used for ALK-positive NSCLC treatment, including crizotinib, alectinib, ceritinib, and brigatinib. Although most adverse events (AEs) of ALK inhibitors are grades 1 to 2 and generally can be well tolerated, serious adverse events (SAEs) of ALK inhibitors lack data analysis, and the lung toxicity of ALK inhibitors needs attention. Thus, we performed this meta-analysis to evaluate the safety of ALK inhibitors, especially in terms of drug-related SAEs.Methods: A total of 19 studies from 4 databases (PubMed, Science Direct, ClinicalTrials.gov and Cochrane Library) were included in this meta-analysis. All statistical analyses in this meta-analysis were performed with the STATA 14.0 software. We analyzed the incidences of total AEs, total SAEs and SAEs for different ALK inhibitors.Results: AEs of the ALK inhibitors occurred in almost all participants, and SAEs occurred in more than 20% of the participants. For ceritinib and brigatinib, SAEs occurred in more than 40% of the participants. Alectinib is most likely the safest of the two generations of ALK inhibitors. Generally, the ALK inhibitors showed significant lung toxicity.Conclusion: In conclusion, attention should be focused on ALK inhibitor-related SAEs, especially lung toxicity. According to this meta-analysis, alxectinib seems to be the safest ALK inhibitor. Physicians should focus on the related SAEs when prescribing ALK inhibitors.Keywords: ALK inhibitors, safety, serious adverse events, lung toxicity |
topic |
ALK inhibitors adverse events serious adverse events lung toxicity |
url |
https://www.dovepress.com/the-safety-and-serious-adverse-events-of-approved-alk-inhibitors-in-ma-peer-reviewed-article-CMAR |
work_keys_str_mv |
AT houh thesafetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT sund thesafetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT liuk thesafetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT jiangm thesafetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT liud thesafetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT zhuj thesafetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT zhoun thesafetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT congj thesafetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT zhangx thesafetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT houh safetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT sund safetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT liuk safetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT jiangm safetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT liud safetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT zhuj safetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT zhoun safetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT congj safetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis AT zhangx safetyandseriousadverseeventsofapprovedalkinhibitorsinmalignanciesametaanalysis |
_version_ |
1725329312509329408 |